company background image
PCRX

Pacira BioSciences NasdaqGS:PCRX Stock Report

Last Price

US$57.85

Market Cap

US$2.6b

7D

0.7%

1Y

-2.4%

Updated

01 Jul, 2022

Data

Company Financials +
PCRX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance1/6
Financial Health2/6
Dividends0/6

PCRX Stock Overview

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States.

Pacira BioSciences Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Pacira BioSciences
Historical stock prices
Current Share PriceUS$57.85
52 Week HighUS$82.16
52 Week LowUS$45.05
Beta0.89
1 Month Change-8.83%
3 Month Change-25.73%
1 Year Change-2.41%
3 Year Change33.73%
5 Year Change14.78%
Change since IPO724.07%

Recent News & Updates

Shareholder Returns

PCRXUS PharmaceuticalsUS Market
7D0.7%-0.7%-2.5%
1Y-2.4%10.4%-21.2%

Return vs Industry: PCRX underperformed the US Pharmaceuticals industry which returned 10.5% over the past year.

Return vs Market: PCRX exceeded the US Market which returned -21.7% over the past year.

Price Volatility

Is PCRX's price volatile compared to industry and market?
PCRX volatility
PCRX Average Weekly Movement6.9%
Pharmaceuticals Industry Average Movement11.9%
Market Average Movement8.1%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: PCRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: PCRX's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006697Dave Stackhttps://www.pacira.com

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure.

Pacira BioSciences Fundamentals Summary

How do Pacira BioSciences's earnings and revenue compare to its market cap?
PCRX fundamental statistics
Market CapUS$2.63b
Earnings (TTM)US$38.44m
Revenue (TTM)US$580.50m

68.4x

P/E Ratio

4.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PCRX income statement (TTM)
RevenueUS$580.50m
Cost of RevenueUS$206.25m
Gross ProfitUS$374.25m
Other ExpensesUS$335.81m
EarningsUS$38.44m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.85
Gross Margin64.47%
Net Profit Margin6.62%
Debt/Equity Ratio130.1%

How did PCRX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is PCRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PCRX?

Other financial metrics that can be useful for relative valuation.

PCRX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.5x
Enterprise Value/EBITDA18x
PEG Ratio3.2x

Price to Earnings Ratio vs Peers

How does PCRX's PE Ratio compare to its peers?

PCRX PE Ratio vs Peers
The above table shows the PE ratio for PCRX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average30.7x
CORT Corcept Therapeutics
24.2x19.8%US$2.7b
PBH Prestige Consumer Healthcare
14.5x5.3%US$3.0b
HRMY Harmony Biosciences Holdings
63.1x43.2%US$3.1b
AMPH Amphastar Pharmaceuticals
21.2xn/aUS$1.7b
PCRX Pacira BioSciences
68.4x21.4%US$2.6b

Price-To-Earnings vs Peers: PCRX is expensive based on its Price-To-Earnings Ratio (68.4x) compared to the peer average (30.7x).


Price to Earnings Ratio vs Industry

How does PCRX's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Earnings vs Industry: PCRX is expensive based on its Price-To-Earnings Ratio (68.4x) compared to the US Pharmaceuticals industry average (22.1x)


Price to Earnings Ratio vs Fair Ratio

What is PCRX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PCRX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio68.4x
Fair PE Ratio23.9x

Price-To-Earnings vs Fair Ratio: PCRX is expensive based on its Price-To-Earnings Ratio (68.4x) compared to the estimated Fair Price-To-Earnings Ratio (23.9x).


Share Price vs Fair Value

What is the Fair Price of PCRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PCRX ($57.85) is trading below our estimate of fair value ($308.13)

Significantly Below Fair Value: PCRX is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: PCRX is poor value based on its PEG Ratio (3.2x)


Discover undervalued companies

Future Growth

How is Pacira BioSciences forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


21.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PCRX's forecast earnings growth (21.4% per year) is above the savings rate (1.9%).

Earnings vs Market: PCRX's earnings (21.4% per year) are forecast to grow faster than the US market (13.6% per year).

High Growth Earnings: PCRX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: PCRX's revenue (11.8% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: PCRX's revenue (11.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PCRX's Return on Equity is forecast to be high in 3 years time (26.3%)


Discover growth companies

Past Performance

How has Pacira BioSciences performed over the past 5 years?

Past Performance Score

1/6

Past Performance Score 1/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


69.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PCRX has a large one-off loss of $48.0M impacting its March 31 2022 financial results.

Growing Profit Margin: PCRX's current net profit margins (6.6%) are lower than last year (33.3%).


Past Earnings Growth Analysis

Earnings Trend: PCRX has become profitable over the past 5 years, growing earnings by 69.9% per year.

Accelerating Growth: PCRX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: PCRX had negative earnings growth (-74%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (19.5%).


Return on Equity

High ROE: PCRX's Return on Equity (5.4%) is considered low.


Discover strong past performing companies

Financial Health

How is Pacira BioSciences's financial position?

Financial Health Score

2/6

Financial Health Score 2/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: PCRX's short term assets ($667.0M) exceed its short term liabilities ($305.1M).

Long Term Liabilities: PCRX's short term assets ($667.0M) do not cover its long term liabilities ($876.8M).


Debt to Equity History and Analysis

Debt Level: PCRX's net debt to equity ratio (66.4%) is considered high.

Reducing Debt: PCRX's debt to equity ratio has increased from 98.6% to 130.1% over the past 5 years.

Debt Coverage: PCRX's debt is not well covered by operating cash flow (15.6%).

Interest Coverage: PCRX's interest payments on its debt are well covered by EBIT (3.9x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Pacira BioSciences's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate PCRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PCRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PCRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PCRX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PCRX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Dave Stack (72 yo)

14.58yrs

Tenure

US$10,136,913

Compensation

Mr. David M. Stack, also known as Dave, has been the Chief Executive Officer of Pacira Pharmaceuticals Inc. Since November 2007, Mr. Stack serves as Director of CODA Biotherapeutics Inc. since December 202...


CEO Compensation Analysis

Compensation vs Market: Dave's total compensation ($USD10.14M) is above average for companies of similar size in the US market ($USD6.90M).

Compensation vs Earnings: Dave's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: PCRX's management team is considered experienced (3.8 years average tenure).


Board Members

Experienced Board: PCRX's board of directors are seasoned and experienced ( 11 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PCRX insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.2%.


Top Shareholders

Company Information

Pacira BioSciences, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Pacira BioSciences, Inc.
  • Ticker: PCRX
  • Exchange: NasdaqGS
  • Founded: 2006
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$2.629b
  • Shares outstanding: 45.44m
  • Website: https://www.pacira.com

Number of Employees


Location

  • Pacira BioSciences, Inc.
  • 5401 West Kennedy Boulevard
  • Suite 890
  • Tampa
  • Florida
  • 33609
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/01 00:00
End of Day Share Price2022/07/01 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.